1. Home
  2. NAK vs CCCC Comparison

NAK vs CCCC Comparison

Compare NAK & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northern Dynasty Minerals Ltd.

NAK

Northern Dynasty Minerals Ltd.

N/A

Current Price

$0.41

Market Cap

320.3M

ML Signal

N/A

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

N/A

Current Price

$2.52

Market Cap

363.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NAK
CCCC
Founded
1983
2015
Country
Canada
United States
Employees
12
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
320.3M
363.7M
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
NAK
CCCC
Price
$0.41
$2.52
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $12.50
AVG Volume (30 Days)
★ 4.2M
2.7M
Earning Date
12-01-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 16.45
EPS
★ N/A
N/A
Revenue
N/A
★ $35,947,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1.02
52 Week Low
$0.51
$1.69
52 Week High
$2.66
$5.17

Technical Indicators

Market Signals
Indicator
NAK
CCCC
Relative Strength Index (RSI) 21.72 34.70
Support Level N/A $2.47
Resistance Level $1.79 $3.25
Average True Range (ATR) 0.06 0.23
MACD 0.00 -0.06
Stochastic Oscillator 0.00 16.75

Price Performance

Historical Comparison
NAK
CCCC

About NAK Northern Dynasty Minerals Ltd.

Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: